UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 12,667 Shares of Zimmer Biomet Holdings, Inc. $ZBH

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,457,553 shares of the medical equipment provider’s stock after selling 12,667 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Zimmer Biomet were worth $125,481,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. OMERS ADMINISTRATION Corp bought a new position in Zimmer Biomet in the 2nd quarter worth about $922,000. Hsbc Holdings PLC bought a new stake in Zimmer Biomet during the 2nd quarter valued at about $35,417,000. PNC Financial Services Group Inc. increased its stake in Zimmer Biomet by 9.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock valued at $14,495,000 after purchasing an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC raised its holdings in Zimmer Biomet by 235.4% in the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock worth $5,204,000 after buying an additional 40,610 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Zimmer Biomet by 257.2% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider’s stock worth $3,091,000 after buying an additional 24,748 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Down 0.5%

Shares of Zimmer Biomet stock opened at $99.52 on Wednesday. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $106.88. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The company’s 50 day moving average is $94.38 and its 200 day moving average is $91.55. The company has a market cap of $18.98 billion, a price-to-earnings ratio of 24.21, a price-to-earnings-growth ratio of 1.89 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm’s revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is presently 23.36%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus increased their price target on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Royal Bank Of Canada upped their price objective on Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Canaccord Genuity Group increased their target price on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Finally, Sanford C. Bernstein lifted their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $104.42.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.